Cargando…

Insights from patients screened but not randomised in the HYPERION trial

BACKGROUND: Few data are available about outcomes of patients screened for, but not enrolled in, randomised clinical trials. METHODS: We retrospectively reviewed patients who had non-inclusion criteria for the HYPERION trial comparing 33 °C to 37 °C in patients comatose after cardiac arrest in non-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lascarrou, J. B., Muller, Gregoire, Quenot, Jean-Pierre, Massart, Nicolas, Landais, Mickael, Asfar, Pierre, Frat, Jean-Pierre, Chakarian, Jean-Charles, Sirodot, Michel, Francois, Bruno, Grillet, Guillaume, Vimeux, Sylvie, Delahaye, Arnaud, Legriel, Stéphane, Thevenin, Didier, Reignier, Jean, Colin, Gwenhael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590986/
https://www.ncbi.nlm.nih.gov/pubmed/34778914
http://dx.doi.org/10.1186/s13613-021-00947-w
_version_ 1784599112166932480
author Lascarrou, J. B.
Muller, Gregoire
Quenot, Jean-Pierre
Massart, Nicolas
Landais, Mickael
Asfar, Pierre
Frat, Jean-Pierre
Chakarian, Jean-Charles
Sirodot, Michel
Francois, Bruno
Grillet, Guillaume
Vimeux, Sylvie
Delahaye, Arnaud
Legriel, Stéphane
Thevenin, Didier
Reignier, Jean
Colin, Gwenhael
author_facet Lascarrou, J. B.
Muller, Gregoire
Quenot, Jean-Pierre
Massart, Nicolas
Landais, Mickael
Asfar, Pierre
Frat, Jean-Pierre
Chakarian, Jean-Charles
Sirodot, Michel
Francois, Bruno
Grillet, Guillaume
Vimeux, Sylvie
Delahaye, Arnaud
Legriel, Stéphane
Thevenin, Didier
Reignier, Jean
Colin, Gwenhael
author_sort Lascarrou, J. B.
collection PubMed
description BACKGROUND: Few data are available about outcomes of patients screened for, but not enrolled in, randomised clinical trials. METHODS: We retrospectively reviewed patients who had non-inclusion criteria for the HYPERION trial comparing 33 °C to 37 °C in patients comatose after cardiac arrest in non-shockable rhythm, due to any cause. A good neurological outcome was defined as a day-90 Cerebral Performance Category score of 1 or 2. RESULTS: Of the 1144 patients with non-inclusion criteria, 1130 had day-90 information and, among these, 158 (14%) had good functional outcomes, compared to 7.9% overall in the HYPERION trial (10.2% with and 5.7% without hypothermia). Considerable centre-to-centre variability was found in the proportion of non-included patients who received hypothermia (0% to 83.8%) and who had good day-90 functional outcomes (0% to 31.3%). The proportion of patients with a good day-90 functional outcome was significantly higher with than without hypothermia (18.5% vs. 11.9%, P = 0.003). CONCLUSION: Our finding of better functional outcomes without than with inclusion in the HYPERION trial, despite most non-inclusion criteria being of adverse prognostic significance (e.g., long no-flow and low-flow times and haemodynamic instability), raises important questions about the choice of patient selection criteria and the applicability of trial results to everyday practice. At present, reserving hypothermia for patients without predictors of poor prognosis seems open to criticism. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13613-021-00947-w.
format Online
Article
Text
id pubmed-8590986
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-85909862021-11-24 Insights from patients screened but not randomised in the HYPERION trial Lascarrou, J. B. Muller, Gregoire Quenot, Jean-Pierre Massart, Nicolas Landais, Mickael Asfar, Pierre Frat, Jean-Pierre Chakarian, Jean-Charles Sirodot, Michel Francois, Bruno Grillet, Guillaume Vimeux, Sylvie Delahaye, Arnaud Legriel, Stéphane Thevenin, Didier Reignier, Jean Colin, Gwenhael Ann Intensive Care Research BACKGROUND: Few data are available about outcomes of patients screened for, but not enrolled in, randomised clinical trials. METHODS: We retrospectively reviewed patients who had non-inclusion criteria for the HYPERION trial comparing 33 °C to 37 °C in patients comatose after cardiac arrest in non-shockable rhythm, due to any cause. A good neurological outcome was defined as a day-90 Cerebral Performance Category score of 1 or 2. RESULTS: Of the 1144 patients with non-inclusion criteria, 1130 had day-90 information and, among these, 158 (14%) had good functional outcomes, compared to 7.9% overall in the HYPERION trial (10.2% with and 5.7% without hypothermia). Considerable centre-to-centre variability was found in the proportion of non-included patients who received hypothermia (0% to 83.8%) and who had good day-90 functional outcomes (0% to 31.3%). The proportion of patients with a good day-90 functional outcome was significantly higher with than without hypothermia (18.5% vs. 11.9%, P = 0.003). CONCLUSION: Our finding of better functional outcomes without than with inclusion in the HYPERION trial, despite most non-inclusion criteria being of adverse prognostic significance (e.g., long no-flow and low-flow times and haemodynamic instability), raises important questions about the choice of patient selection criteria and the applicability of trial results to everyday practice. At present, reserving hypothermia for patients without predictors of poor prognosis seems open to criticism. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13613-021-00947-w. Springer International Publishing 2021-11-14 /pmc/articles/PMC8590986/ /pubmed/34778914 http://dx.doi.org/10.1186/s13613-021-00947-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Lascarrou, J. B.
Muller, Gregoire
Quenot, Jean-Pierre
Massart, Nicolas
Landais, Mickael
Asfar, Pierre
Frat, Jean-Pierre
Chakarian, Jean-Charles
Sirodot, Michel
Francois, Bruno
Grillet, Guillaume
Vimeux, Sylvie
Delahaye, Arnaud
Legriel, Stéphane
Thevenin, Didier
Reignier, Jean
Colin, Gwenhael
Insights from patients screened but not randomised in the HYPERION trial
title Insights from patients screened but not randomised in the HYPERION trial
title_full Insights from patients screened but not randomised in the HYPERION trial
title_fullStr Insights from patients screened but not randomised in the HYPERION trial
title_full_unstemmed Insights from patients screened but not randomised in the HYPERION trial
title_short Insights from patients screened but not randomised in the HYPERION trial
title_sort insights from patients screened but not randomised in the hyperion trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590986/
https://www.ncbi.nlm.nih.gov/pubmed/34778914
http://dx.doi.org/10.1186/s13613-021-00947-w
work_keys_str_mv AT lascarroujb insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT mullergregoire insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT quenotjeanpierre insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT massartnicolas insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT landaismickael insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT asfarpierre insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT fratjeanpierre insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT chakarianjeancharles insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT sirodotmichel insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT francoisbruno insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT grilletguillaume insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT vimeuxsylvie insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT delahayearnaud insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT legrielstephane insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT thevenindidier insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT reignierjean insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT colingwenhael insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial
AT insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial